Canntab Therapeutics Limited
CTABFOTCHealthcare
$0.00
+$0.00(+0.00%)
Market Cap$3891
P/E Ratio—
52W High$0.0073
52W Low$0.0001
Canntab Therapeutics Limited (CTABF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CTABF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-05 | 2021-05 | 2020-05 | 2019-05 | 2018-05 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.29M | $0.00M | $0.13M | $0.24M | $0.03M |
| Cost of Revenue | $1.23M | $0.26M | $0.00M | $0.10M | $0.00M |
| Gross Profit | ($0.94M) | ($0.26M) | $0.13M | $0.14M | $0.03M |
| Gross Margin %(computed) | -320.09% | — | 100.00% | 59.84% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.21M | $0.08M | $0.11M | $0.13M | $0.14M |
| G&A Expenses | $2.60M | $2.58M | $2.14M | $2.44M | $2.13M |
| Total Operating Expenses | $3.23M | $3.26M | $2.75M | $2.74M | $2.45M |
| Operating Income | ($4.16M) | ($3.52M) | ($2.62M) | ($2.50M) | ($2.42M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.04M | $0.02M |
| Interest Expense | $0.57M | $0.19M | $0.03M | $0.00M | $0.00M |
| Income Before Tax | ($3.69M) | ($4.42M) | ($2.61M) | ($2.46M) | ($2.41M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($3.69M) | ($4.42M) | ($2.61M) | ($2.46M) | ($2.41M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.10 | $-0.13 | $-0.10 | $-0.10 | $-0.11 |
| Wtd Avg Shares | 37.72M | 34.55M | 27.17M | 25.30M | 21.13M |
| EBITDA | ($2.49M) | ($3.13M) | ($2.29M) | ($2.42M) | ($2.37M) |
| EBITDA Margin %(computed) | -848.03% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CAD · M
Explore more Canntab Therapeutics Limited data
About Canntab Therapeutics Limited (CTABF) Income Statement
Canntab Therapeutics Limited (CTABF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, CTABF reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -320.09%), and net income of ($0.00B) — a net profit margin of -1257.55%.
Frequently asked questions
CTABF · 4 questionsCanntab Therapeutics Limited (CTABF) reported revenue of $0.00B for 2022, up —% year-over-year.
CTABF revenueCTABF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09